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Abstract: Parkinson’s disease (PD) is a neurodegenerative disorder defined by progressive
deterioration of dopaminergic neurons in the substantia nigra pars compacta (SNpc). Dental pulp
stem cells (DPSCs) have been proposed to replace the degenerated dopaminergic neurons due to
its inherent neurogenic and regenerative potential. However, the effective delivery and homing of
DPSCs within the lesioned brain has been one of the many obstacles faced in cell-based therapy
of neurodegenerative disorders. We hypothesized that DPSCs, delivered intranasally, could
circumvent these challenges. In the present study, we investigated the therapeutic efficacy of
intranasally administered DPSCs in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced
mouse model of PD. Human deciduous DPSCs were cultured, pre-labelled with PKH 26, and
intranasally delivered into PD mice following MPTP treatment. Behavioural analyses were performed
to measure olfactory function and sensorimotor coordination, while tyrosine hydroxylase (TH)
immunofluorescence was used to evaluate MPTP neurotoxicity in SNpc neurons. Upon intranasal
delivery, degenerated TH-positive neurons were ameliorated, while deterioration in behavioural
performances was significantly enhanced. Thus, the intranasal approach enriched cell delivery to
the brain, optimizing its therapeutic potential through its efficacious delivery and protection against
dopaminergic neuron degeneration.
Keywords: Parkinson’s disease; dental pulp stem cells; MPTP; intranasal delivery; behavioural
analysis; tyrosine hydroxylase
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1. Introduction
Parkinson’s disease (PD) is regarded as the most common degenerative disorder of the aging
brain, following Alzheimer’s [1,2]. It is mainly characterized by tremors, bradykinesia, rigidity, and
postural instability that results primarily from the extended loss of dopaminergic (DA) neurons in
the substantia nigra (SN) [3]. Currently there is no cure for PD and most available treatments aim to
reverse the dopamine deficiency and relieve its symptoms [4,5]. At present, stem-cell-based therapies
are being investigated for their ability to reproduce functional dopaminergic neurons and replace
degenerated neurons in the SN [4,6–9]. However, the ability of stem cells to produce functional
neuronal cells and promote therapeutic efficacy in vivo needs to be demonstrated before they can
be applied clinically [10–12]. Thus, obtaining a high-purity population of dopaminergic-like cells
is critical for the development of stem-cell-based therapies for PD. Although mesenchymal stem
cells (MSCs) have previously been shown to exert neuroprotection through the secretion of nerve
growth factors, they rarely differentiate into functional neural cells. Additionally, due to the low
incidence of adult neural stem cells (NSCs) and issues with harvesting, the utilization of other stem
cell types with neural potential is required to achieve neuroregeneration [12–16]. Recently, DPSCs
have been increasingly gaining prominence in the field of stem cell therapy for neurodegenerative
diseases [8,17–21]. In fact, among all exploitable stem/progenitor cells, these cells have emerged as
one of the best choices due to unique properties such as easy accessibility, clonogenicity, self-renewal
and potency. Indeed, due to their neural crest origin, DPSCs displayed high plasticity and are
particularly able to differentiate towards neural lineage. In vitro neural differentiation studies of rat
and human DPSCs have previously demonstrated that these stem/precursor cell populations were
able to differentiate into neurons based on cellular morphology and expression of early neuronal
markers [4,19,20,22,23]. Above all, in vivo studies further revealed that rat DPSCs, when transplanted
into an adult rodent brain, survived and expressed neuronal markers [10,17,18]. Thus, the recent
development of clinically applicable populations of DPSCs has provided an avenue to overcome
the failure of endogenous repair systems and substitute new cells into the lesioned brain [10,12].
Nevertheless, there are several existing obstacles concerning the utilization of DPSCs before translation
into clinical application is made possible. One of the potential challenges that currently exist for stem
cell therapy is the lack of safe and efficient cell delivery methods [24,25]. It has been reported that
graft survival, sufficient enrichment of therapeutic cells in the brain, and the avoidance of stem cell
distribution throughout peripheral organs are greatly influenced by the method of delivery [13–15].
At present, the routes used for stem cell delivery to the brain are either invasive or inefficacious due to
the blood-brain barrier (BBB). Numerous complications have been stated previously in successfully
administrating these stem cells for therapeutic purposes [25]. Lately, however, a few studies have
explored the nasal system as a novel stem cell delivery route to the brain where the intranasal delivery
of stem cells were able to circumvent the blood-brain barrier (BBB) and directly target the brain to
treat PD [16,26,27]. Intranasally delivered MSCs have been shown to migrate through the cribriform
plate and into brain tissue via olfactory and trigeminal pathways. Not only were the stem cells
located in discrete regions of the brain but the delivery of MSCs appeared to have a therapeutic
effect on PD animal models [16]. Currently, there are not many studies on stem cells in neurological
diseases using intranasal delivery as the route of stem cell delivery to the brain. Although previous
studies have demonstrated the underlying biology and cellular properties of DPSCs, the long-term
survival and therapeutic impact of intranasally delivered DPSCs on PD experimental models has
remained unexplored [6]. In this study, we examined the survival and differentiation of these cells
upon intranasal administration into MPTP-induced mice models of PD. Our findings revealed that
DPSCs delivered via intranasal application survived for a period of one month, differentiated into
dopaminergic-like cells, and gradually enhanced the previously depleted dopaminergic activity of the
nigrostriatal system following MPTP toxicity. Above all, intranasally administered DPSCs prominently
ameliorated the MPTP-induced deficits observed in sensorimotor coordination and olfactory function
of Parkinsonian mice.
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2. Results
2.1. Basic Characterization of Isolated DPSCs
The isolated DPSCs displayed a fibroblastic-type morphology resembling to that of bone marrow
MSCs (Figure 1i,ii). The cells formed a homogenous monolayer of adherent, spindle-shaped,
fibroblast-like cells that proliferated fast and reached confluency after 10–12 days. Flow cytometry
analysis further revealed that these cells expressed characteristic antigens of MSC-like cells including
CD73, CD90 and CD166 but did not express HLA-DR and hematopoietic markers CD34 and CD45
(Figure 1iii).
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Figure 1. (i) Primary culture images obtained from 6 assays displaying the morphology of DPSCs
(Magnification 4×; phase contrast images) (ii) Images of DPSCs expanded in FBS at subculture 3
(A: Magnification at 10×; B: Magnification at 20×; phase contrast images) (iii) Immunophenotype
analysis of DPSCs expanded in FBS using flow cytometry. Cells were tested against human antigens
CD34, CD45, CD73, CD90, CD166, and HLA-DR.
2.2. Differentiation of DPSCs into Dopaminergic Neuron-Like C lls
Real-time PCR analysis indicated that gene expression profile of DPSCs was more consistent with
mature neuronal cells, following neuronal induction. Pluripotent markers SOX 2, OCT-4 and early
neuronal marker NESTIN were slightly downregulated, while mid-neuronal gene NURR1 and mature
neuronal markers B-Tub, TH, DAT and MAP-2 had increased expression in induced DPSCs (Figure 2).
Collectively, these data suggest that, in response to neuronal inductive stimuli, a greater proportion of
DPSCs had stopped proliferating and had acquired a phenotype resembling mature neurons.
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MPTP impaired sensorimotor coordination in mice following its administration at day 0, as
shown in the time taken to (A) traverse the beam, (B) the number of errors made per step, (C) the
number of spontaneous rears made on hindlimbs and (D) the time taken to make contact with sensory 
stimuli (p < 0.001) (Figure 3). However, intranasal delivery of undifferentiated DPSCs at Day 7 
gradually reversed this impairment one week later, across all measures (p < 0.001). Similarly, MPTP 
reduced olfactory function in mice following its administration at Day 0, as shown in the time taken 
to Figure 3A discover the hidden pellet and Figure 3B–D discriminate between their own scent and
to that of a conspecific (p < 0.001) (Figure 4). The olfactory performance was significantly improved 
in MPTP mice across both tests following DPSC delivery at Day 7 (p < 0.001). 
Figure 2. Detection of pluripotent indicators as well as neuronal markers. The Ct value of genes was
analysed in the study using SYBR green-based qRT–PCR for DPSCs. Generally, the higher a fold change
value, the more copies are present in the specific sample. Total RNA from brain was used as a positive
control. Values are presented after normalization to 18s mRNA levels (p < 0.05).
2.3. Recovery of Neurological Behaviour in Parkinsonian Mice Following Intranasal Application of DPSCs
MPTP impaired sensorimotor coordination in mice following its administration at day 0, as shown
in the time taken to (A) traverse the beam, (B) the number of errors made per step, (C) the number of
spontaneous rears made on hindlimbs and (D) the time taken to make contact with sensory stimuli
(p < 0.001) (Figure 3). However, intranasal delivery of undifferentiated DPSCs at Day 7 gradually
reversed this impairment one week later, across all measures (p < 0.001). Similarly, MPTP reduced
olfactory function in mice following its administration at Day 0, as shown in the time taken to Figure 3A
discover the hidden pellet and Figure 3B–D discriminate between their own scent and to that of a
conspecific (p < 0.001) (Figure 4). The olfactory performance was significantly improved in MPTP mice
across both tests following DPSC delivery at Day 7 (p < 0.001).
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Figure 3. Control, MPTP-induced and DPSC-administered MPTP mice were tested for sensorimotor
coordination on the challenging beam traversal, spontaneous activity in cylinder and adhesive removal
tests. (A) The time taken to traverse the beam, (B) the number of errors made per step, (C) the number
of spontaneous rears made on the hindlimbs and (D) the time taken to make contact with the sensory
stimuli were measured. MPTP mice took longer to traverse the beam and made more errors during
steps compared with the control mice in the beam test. In addition, MPTP mice were less active in the
cylinder test and were significantly slower to respond to sensory stimuli compared with the control
mice in the adhesive removal test. However, performance was significantly improved in MPTP mice
across all measures following DPSC delivery (red arrow) at Day 7 (p < 0.001). Values are expressed as
mean ± SD.
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Figure 5A. MPTP exposure at Day 0 led to a marked loss of TH-positive neurons one week later 
within the SN for the vehicle group. In the control group, TH immunohistochemical staining was 
highly expressed in the cytoplasm of dopaminergic neurons, whose processes were elongated and 
stained clearly. In MPTP-treated animals, dopaminergic neurons in SN showed light sparse TH-
immunostaining with short and disorderly processes. Following the treatment of undifferentiated 
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the time of DPSC administration. The mice treated with intranasal DPSCs also showed increased 
Figure 4. Control, MPTP-induced and DPSC-administered MPTP mice were tested for olfactory
function on the buried pellet test and the block test. The time taken to (A) discover the hidden pellet
and (B–D) to discriminate between their own scent and to that of a conspecific were measured. The
block test was divided into three levels with increased complexity. MPTP mice took longer to find the
hidden pellet and recognize foreign odour when compared with control mice in the buried pellet and
block tests respectively. However, olfactory function was significantly improved in MPTP mice across
both tests following DPSC delivery (red arrow) at Day 7 (p < 0.001). Values are expressed as mean
± SD.
2.4. Intranasal DPSC Application Rescued Dopaminergic Neurons from MPTP Toxicity
The MPTP injection was targeted at the Substantia Nigra (SN) as illustrated in the coronal
mesencephalon sections immunostained for TH displaying the varying degrees of degeneration
in Figure 5A. MPTP exposure at Day 0 led to a marked loss of TH-positive neurons one week
later within the SN for the vehicle group. In the control group, TH immunohistochemical staining
as highly expressed in the cytoplasm of dopaminergic neurons, whose processes were elongated
and stained clearly. In MPTP-treated animals, dopaminergic neurons in SN showed light sparse
TH-immunostaining with short and disorderly rocesses. Following the treatment of undifferentiated
DPSCs, there were gradual enhancements of TH immunoreactivity every week for four weeks from
the time of DPSC administration. The mice treated with intranasal DPSCs also showed increased
structural integrity and more co densation of immunoreactivity in the SN than t at of the MPTP
vehicle group.
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(c) Treatment group: MPTP + DPSCs (two weeks after DPSC delivery) (d)Treatment group: MPTP + 
DPSCs (four weeks after DPSC delivery). The DPSCs labelled with PKH26 were delivered to MPTP 
mice at Day 7. Mice were lesioned with MPTP at Day 0. (B) Survival and migration of the PKH-
labelled DPSCs within the SNpc following intranasal administration. PKH26 fluorescence 
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induced PD mice following intranasal delivery. In a study by Danielyan et al. (2011), the beneficial 
effects of intranasal delivery of therapeutic MSCs were shown in PD animal models as a non-invasive 
alternative to the current traumatic surgical procedure of transplantation [16]. It was revealed that 
chronic treatment using the intranasal delivery method increased the number of delivered cells to the 
brain and enhanced its therapeutic benefit. Based on these results, we envisioned that the intranasal 
application of DPSCs might be more effective for developing therapeutic interventions for PD. Here, 
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Figure 5. (A) Pictures displaying the effects of MPTP and intranasally administered DPSCs on tyrosine
hydroxylase (TH) expression in the substantia nigra pars compacta (SNpc) of MPTP induced mice.
(i–iii) Photomicrographs showing TH expression within the SNpc at low (5×), medium (10×) and
high magnification (20×). (a): Control group at day 0 (b): Vehicle group: MPTP + saline at Day 7
(c) Treatment group: MPTP + DPSCs (two weeks after DPSC delivery) (d)Treatment group: MPTP +
DPSCs (four weeks after DPSC delivery). The DPSCs labelled with PKH26 were delivered to MPTP
mice at Day 7. Mice were lesioned with MPTP at Day 0. (B) Survival and migration of the PKH-labelled
DPSCs within the SNpc following intranasal administration. PKH26 fluorescence visualization proved
the existence of cell deposits in the SN (red arrow) of all grafted animals, indicating cell survival for at
least four weeks after intranasal delivery (photomicrographs at high (20×) magnification).
2.5. Fluorescent Imaging of DPSCs In Vivo
PKH26-labelled DPSCs were intranasally administered at Day 7 and, even after four weeks,
labelled cells were detected and primarily distributed within the SN (red arrow) (Figure 5B).
This suggests that DPSCs showed the ability to migrate, engraft and survive within the SN.
3. Discussion
The in vitro differentiation ability of DPSCs towards dopaminergic-like cells and their
neurorestorative capacities in MPTP-induced mice upon intrathecal administration has been shown
previously [28,29]. In view of the difficulties associated with the intrathecal mode of delivery,
the present study examined the neuroprotective efficacy of undifferentiated deciduous DPSCs in
MPTP-induced PD mice following intranasal delivery. In a study by Danielyan et al. (2011), the
beneficial effects of intranasal delivery of therapeutic MSCs were shown in PD animal models as a
non-invasive alternative to the current traumatic surgical procedure of transplantation [16]. It was
revealed that chronic treatment using the intranasal delivery method increased the number of delivered
cells to the brain and enhanced its therapeutic benefit. Based on these results, we envisioned that
the intranasal application of DPSCs might be more effective for developing therapeutic interventions
for PD. Here, we demonstrated that the expression of cell surface and intracellular markers by
DPSCs indicated their primitive features. The isolated stem cells from deciduous dental pulp tissue
displayed a property of plastic adherence, expanded consistently and had a homogeneous fibroblastic
morphology that was similar to that of bone marrow MSCs [4,30,31]. These stem cells shared a common
mesenchymal marker profile with MSCs derived from bone marrow [18,29,32,33]. Following neural
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induction in vitro, the induced cells were characterized by an increase in mature neuronal markers,
accompanied by a simultaneous decrease in early neuronal markers. Thus, our in vitro studies support
the notion that at least a proportion of stem cells derived from dental pulp tissues may be capable of
differentiating into neuronal cells when cultured under appropriate inductive conditions.
Remarkably, upon intranasal administration, the stem cells from dental origin effectively protected
against the MPTP-induced deficits observed in behavioural assessments that examined sensorimotor
coordination and olfactory function. In the first week following MPTP treatment, sensorimotor
tests and olfactory assays displayed significant decreases in performance, which was a direct result
from the loss of nigral dopaminergic neurons induced by MPTP neurotoxicity. This reduction
however, was counteracted by the intranasal management of undifferentiated DPSCs on Day 7,
as a marked progressive improvement was observed in sensorimotor coordination and olfactory
function on mice treated with DPSCs, compared to the vehicle-treated animals. Additionally, we
found that differentiated DPSCs protected against the loss of TH-positive neurons by migrating
towards the SN and gradually attenuating the reduction in TH-positive neurons induced by MPTP
neurotoxicity. Taken together, we have shown that DPSCs applied via the nasal route were able to
migrate, survive, integrate into the host brain and appropriately differentiate into dopaminergic-like
cells. Above all, the intranasal delivery of DPSCs enhanced cell delivery to the brain and optimized
the therapeutic potential of DPSCs by protecting against dopaminergic neuronal degeneration and
improving host neurological function. These findings, along with those of other studies concerning
the migration and fate of undifferentiated DPSCs in vivo, demonstrate the great promise of this
emerging paradigm. Nonetheless, before this potential can be realized in a clinical setting, future
studies should include an in depth understanding of the molecular mechanisms governing their
migratory properties and above all, the pattern and kinetics of DPSC colonization across various
brain regions if these cells are to be used therapeutically in humans. The study on distribution of
DPSCs across various brain regions would be particularly interesting taking into consideration that
the presence of these cells is low in the mesencephalon. Our current study has not investigated the
complete distribution of DPSCs in the brain, as it was beyond the scope of the study. The efficient
migration and colonization of DPSCs toward regions of pathology in the brain followed by their
successful integration, differentiation, and long-term survival at these sites is required for effective
stem cell-mediated treatment of PD. Currently, there is a lack of consistency in certain areas of DPSC
therapeutics and the potential of immunomodulatory properties of DPSCs is remarkable in order to
form the basis of future therapeutics. Most studies conducted till date have not clearly displayed much
support towards differentiation and engraftment but unanimously supported its immunomodulating
properties. Thus far, it is evident that DPSCs are able to modulate immune cells and escape immune
rejection, depending on its microenvironment. Recent reports have proposed that the inflammatory
environment associated with PD might alter the DPSC polarization towards immunosuppressive
or immunostimulating phenotype [10,20]. Consequently, further studies should be aimed towards
understanding the mechanisms underlying immunomodulation by DPSCs to be able to utilize DPSCs
for therapeutic purposes.
4. Materials and Methods
4.1. Isolation and Culture of DPSCs
The DPSCs were obtained from Hygieia Therapeutics Sdn. Bhd, Putrajaya, Malaysia and the
following procedure was employed by them to isolate and culture DPSCs that were provided for
our study. Upon receiving informed consent from donors’ parents, sound intact deciduous molars
were extracted from children (5–8 years of age) undergoing planned serial extractions (n = 5) at
the Department of Children Dentistry and Orthodontics, Faculty of Dentistry, University of Malaya.
Samples were obtained under a protocol that was approved by the Medical Ethics Committee, Faculty
of Dentistry, University of Malaya (Medical Ethics Clearance Number: DFCD0907/0042[L]; Date of
Int. J. Mol. Sci. 2019, 20, 568 9 of 13
approval: 01/09/2009). DPSC primary cultures from deciduous teeth were established as previously
described by Govindasamy et al. (2010) [22]. In brief, cells were cultured in identical culture condition,
with culture medium containing 1× KO-DMEM, 200 U/mL and 200 µg/mL of penicillin/streptomycin
(Invitrogen, Carlsbad, CA, USA); 0.01× Glutamax (Invitrogen) and 10% foetal bovine serum (FBS)
(Invitrogen) with humidified atmosphere of 95% of air and 5% of CO2 at 37 ◦C. Non-adherent cells
were removed 48 h after initial plating. The medium was replaced every three days until the cells
reached 80–90% confluency.
4.2. Flow Cytometric Analysis
Immunophenotyping of deciduous DPSCs were examined using flow cytometry at passage
5 [22]. The antibodies used to mark the cell surface epitopes were CD90-phycoerythrin (PE),
CD73-PE, CD166-PE and CD34-PE, CD45-fluoroisothiocyanate (FITC), and HLA-DR-FITC (all from
BD Pharmingen, San Jose, CA, USA). All analyses were standardized against negative control cells
incubated with isotype-specific immunoglobulin (Ig) G1-PE and IgG1-FITC (BD Pharmingen). At least
10,000 events were acquired on a Guava Technologies flow cytometer, and the results were analysed
using Cytosoft, Version 5.2 (Guava Technologies, Hayward, CA, USA).
4.3. Induction of Dopaminergic Neuronal Differentiation
DPSCs were subjected to neuronal induction using chemically defined media as described
by Wang et al. (2010) [34]. Briefly, DPSCs were co-cultured with conditioned medium (CM) of
ReNCell VM (Merck Milipore, Darmstadt, Hesse, Germany) for seven days before being exposed to
Neuronal Media A containing Neurobasal A, B27 supplement, 20 ng mL−1 basic fibroblast growth
factor (bFGF) and 20 ng mL−1 epidermal growth factor (EGF) for nine days, and Neuronal Media
B containing Neurobasal A, 200 ng mL−1 sonic hedgehog (SHH), 100 ng mL−1 fibroblast growth
factor 8 (FGF8), 10 ng mL−1 brain-derived neurotrophic factor (BDNF) and 10 µmol L−1 forskolin
(Sigma-Aldrich, St. Louis, MO, USA) for seven days. All chemicals were purchased from Invitrogen
unless stated otherwise.
4.4. Real-Time Polymerase Chain Reaction
Total RNA was extracted at the end of induction period using TRIzol (Invitrogen) and converted
to cDNA according to Govindasamy et al. 2010 [22]. Gene expression levels were quantified in
duplicates via real-time PCR, using SYBR Green Master Mix (Applied Biosystems, Foster City, CA,
USA). PCR reactions were carried out on ABI 7900HT RT–PCR system (Applied Biosystems), and the
results were analysed with the SDS v. 2.1 software. Gene expressions were analysed via comparative
CT Method (∆∆Ct) and were normalized to 18s rRNA. The gene expression was compared against
undifferentiated cells as a control group and the primer sequences are listed in Table 1.
Table 1. List of genes with primer sequence and their product size.
Gene Name Forward Sequence (5′–3′) Reverse Sequence (5′–3′) Base Pair Size
SOX 2 GGACAGTTACGCGCACATGA AGCCGTTCATGTAGGTCTGC 188
OCT 4 TCCCGAATGGAAAGGGGAGA GGCTGAATACCTTCCCAAATAGA 209
NES GTAGCTCCCAGAGAGGGGAA CTCTAGAGGGCCAGGGACTT 206
NR4A2 CGCCTGTAACTCGGCTGAA AGTGTTGGTGAGGTCCATGC 169
TUBB3 GCGAGATGTACGAAGACGAC TTTAGACACTGCTGGCTTCG 115
NCAM TCTGCTAGCTCGTCTACCCC AGCTTAGGTGCACTGGGTTC 110
MAP2 TAGAGGGTGTGATGGCTGAG GGCAGAGGAAGGGATTTCTA 183
TH TCATCACCTGGTCACCAAGTT GGTCGCCGTGCCTGTACT 125
DAT AAAGTCCTTTCCCGATGCGT ATACCAGGACCCCCATCCTC 111
18s rRNA CGGCTACCATCCAAGGAA GCTGGAATTACCGCGGCT 186
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4.5. Animals
Sixty male Swiss albino mice (25–30 g and 10–12 weeks old) were randomly assigned into three
groups: Control, MPTP-treated and MPTP-treated-intranasal DPSC. Mice were housed five per cage
with food and water ad libitum under fixed temperature (25 ± 2 ◦C) and humidity (60 ± 5%) on a 12-h
light/dark cycle. Ethical approval was obtained from the AIMST University Human and Animal Ethics
Committee (AUHAEC) (application Ref. no.: AUHAEC6/FOM/2014; Date of approval: 19/06/2015).
4.6. Establishment of PD Model
The PD model was induced by injecting MPTP (20 mg/Kg; Sigma-Aldrich) in saline
intraperitoneally, four times a day at 2-h intervals [35].
4.7. Intranasal Application of DPSCs
Intranasal application of DPSCs or vehicle (PBS) into MPTP-lesioned mice was performed seven
days after MPTP injection. Prior to vehicle or cell treatment, mice were treated with 100 U of
hyaluronidase (Sigma-Aldrich) dissolved in 24 µL sterile PBS as four repeated inoculations at 5-min
intervals (3 µL in each nostril). One hour after pre-treatment with hyaluronidase, a DPSC suspension
(5 × 105 in 24 µL sterile PBS) or vehicle (PBS) was applied, following the same procedure [36].
4.8. Fluorescent Imaging of DPSCs in Vivo
DPSCs were tagged with PKH 26 (Sigma-Aldrich), as described by the manufacturer. In brief,
cells were washed twice in a serum-free medium and mixed with a dye solution for 3 min. FBS was
added for neutralization and suspended in saline. Tagged DPSCs were then introduced into mice
via intranasal administration. Fluorescent images of harvested brain tissues were viewed under a
fluorescence microscope (Olympus BX63 microscope; Olympus, Tokyo, Japan) to detect the presence
of cells [9].
4.9. Behaviour Testing
All mice were pre-trained and two weeks prior to MPTP treatment, baseline recordings
were obtained. Behavioural tests were carried out every three days following MPTP and DPSC
treatment. Sensorimotor coordination was measured by the challenging beam traversal test, the
spontaneous activity in cylinder test, and the adhesive removal test, as defined by Fleming et al. [37].
The challenging beam test was comprised of a beam with four sections that gradually decreased in
diameter. Animals were trained to traverse the beam from the widest point to the narrowest and,
during testing, a wire mesh grid was placed over the beam. Animals were videotaped while traversing
the beam and the time taken to traverse the beam was determined. Spontaneous movement was
measured by placing animals in a small transparent cylinder. The number of rear and hindlimb steps
was measured. A rear was counted as when an animal made a vertical movement with both forelimbs
removed from the ground, while hindlimb steps were counted when an animal moved both hindlimbs
across the floor. As for the adhesive removal test, adhesive tape was applied on the snout of the animal
and the time-to-contact and the time-to-removal were measured. To assess the odour detection ability
and the olfactory memory, the buried pellet test and the block test were used [38]. The buried pellet
test was conducted to examine whether the food-deprived animal was able to uncover the food pellet
hidden beneath the cage bedding. The latency to uncover the buried food pellet beneath a layer of
cage bedding, within a limited amount of time, was recorded. The block test, on the contrary, tested
the ability of animals to discriminate between their own scent and that of a conspecific. The animal
was presented with a wooden block scented with its own bedding and a block scented with another
mouse’s bedding. The time spent in contact with each block was recorded. Slight modifications were
made to the arrangement of the blocks in the block test to increase the level of difficulty of identifying
the novel scent.
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4.10. Perfusion and Fixation of Brains
At days 7, 14, 21 and 28 following intranasal application and MPTP treatment, mice were
deeply anesthetized with ketamine/xylazine (Bioniche, Belleville, Toronto, ON, Canada) and perfused
intracardially with saline (0.9%) followed by 4% paraformaldehyde (PFA). Brains were then collected,
post-fixed at 4% PFA overnight, and transferred to 20% sucrose in 0.1 M phosphate-buffered saline
(PBS) for cryoprotection. A set of coronal sections containing the SN (25 µm thickness) were cut on a
microtome (Leica Microsystems, Wetzlar, Hesse, Germany) and stored at −20 ◦C.
4.11. Tyrosine Hydroxylase (TH) Immunostaining
The 25-µm coronal brain sections were rinsed twice in PBS, incubated in 0.2% Triton X-100 for
30 min at RT and rinsed three times with 0.5% bovine serum albumin (BSA) in 1× PBS for blocking.
The brain sections were then incubated overnight at 4 ◦C with primary antibody: mouse anti-tyrosine
hydroxylase (TH, 1:2000 dilution for brain tissue, Pel-freez, Rogers, AR, USA), rinsed three times
in 0.5% BSA in 1× PBS and incubated with the appropriate biotinylated secondary antibody and
avidinebiotin complex (Elite Kit; Vector Laboratories, Burlingame, CA, USA) for 1 h at RT. Bound
antibodies were visualized by incubating with 0.05% diaminobenzidine-HCl and 0.003% hydrogen
peroxide in 0.1M PB. Immunostained cells were analysed by bright-field microscopy [34].
4.12. Statistical Analysis
Results were presented as a comparison of average ± standard deviation (SD). Results obtained
from behavioural data tested for normal distribution assumption and one-way Analysis of Variance
(ANOVA) were used, followed by multiple post hoc comparisons among groups were made using
Tukey’s or Bonferroni test. A p-value of <0.001 was considered significant. Data were analysed using
SPSS version 22.0.
5. Conclusions
In conclusion, we have demonstrated that the intranasal delivery of DPSCs decreased brain lesion
volume by promoting the formation of a ‘neurogenic niche’, ultimately leading to reconstruction of the
Substantia nigra pars compacta. The intranasal approach enriched cell delivery to the brain, optimizing
its therapeutic potential by protecting against dopaminergic neuronal degeneration, which is evident
in the significant improvement of host neurological function.
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